Stocks and Sips - Xenitra Ltd (ASX:XEN)

Held on 7 May 2026, 6:00 PM

Event Recap

At our latest Stocks and Sips event, we welcomed Dr Anthony Noble, Non-Executive Chairman of Xenitra Limited (ASX:XEN), for an in-depth discussion hosted by Sharewise CEO Alex Perry.

Xenitra is one of the few ASX-listed vehicles offering direct exposure to China's fast-growing consumer and healthcare markets. Through its channel-optimised sales platform - spanning B2B trading, retail distribution, and all major Chinese e-commerce platforms - XEN has generated over $70m in sales since 2024 and secured a $30m offtake agreement for global brands. The recent acquisition of Fukang OTC Pharmacy and the launch of the OPAL token and Xen Shop position the company at the intersection of cross-border FMCG, consumer healthcare, and Web3-enabled retail.

Anthony shared insights on:

Xenitra's journey since his appointment as Chairman in March 2025, and what he believes the market may be underappreciating today
Where Xenitra is most differentiated in how it connects global brands with Chinese consumers, and the key drivers behind its recent revenue growth and offtake agreement
The long-term opportunities across XEN's three core categories — nutraceuticals, OTC pharmaceuticals, and tokenisation — and the brand partnership pipeline supporting its next phase of growth
How real-world asset tokenisation works in practice through the OPAL token and Xen Shop, the customer experience it enables, and early commercial outcomes compared with traditional e-commerce models
Xenitra's approach to regulatory risk amid China's evolving stance on digital assets and cross-border e-commerce, and the flexibility built into the model to adapt to changes in the operating environment
The role of the Nutritionals business going forward, following streamlining, cost reductions, and the implementation of a leaner management structure
How investors should think about closing the gap between Xenitra's commercial delivery and broader market sentiment on China-exposed names
The key factors Anthony believes will ultimately determine Xenitra's long-term success

The evening brought together Sharewise clients for thoughtful discussion, live Q&A, and networking over drinks and gourmet food at the Sharewise office in Milsons Point.

🗣️ About Dr Anthony Noble, PhD, MBA

Anthony was appointed Non-Executive Chairman in March 2025. He has more than 20 years’ experience working across life sciences, consumer health, and international trade, with a focus on building partnerships and creating sustainable growth. Anthony holds a PhD in Stem Cell Biology and an Executive MBA from the Australian Graduate School of Management, including a year at the Wharton School (UPenn). His career has spanned from biotechnology research and clinical development to operational and commercial leadership roles in both listed and private companies. He currently serves as Executive Director at Servatus Biopharmaceuticals and Biomiq Skincare. He previously was CEO of The Calmer Co. Ltd and Australian Biotherapeutics. Anthony spent a decade in various roles within the SFI Health Group where he was Global Head of Innovation and spearheaded market expansion initiatives via both organic growth and multiple M&A transactions in Europe, Australia, North America and in Asia, with a strong focus on the North Asia markets, including serving as General Manager of both SFI-Shineway in China and of SFI-Korea. His focus at Xenitra has been on strengthening the company’s compliance and governance practices, tightening and defining the strategic direction, supporting senior management in China, and ensuring the business is well-positioned to take advantage of growing opportunities in cross-border trade.

🏢 About Xenitra Ltd (ASX:XEN)

Xenitra specialises in fast-moving consumer goods (FMCG), nutraceuticals, over-the-counter (OTC) medicine and personal care products that are sold through a channel optimised sales ecosystem including blockchain tokenised distribution channels spanning Business-to-Business (B2B) trading, retail distribution and all major ecommerce platforms in China. Xenitra works with leading international brands as a market entry and sales acceleration partner for Asian markets. Through our proprietary platform, we have a proven track record of delivering exceptional market integration, providing marketing insights and delivering sales velocity for brands in China.